Antiretroviral News and Research

RSS

Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Preventable deaths caused by acute kidney injury (AKI) could be nearly eliminated in just 10 years, according to leading medical experts. This often forgotten condition - which affects around 13 million people every year and contributes to 1.7 million deaths annually - is preventable and can be treated for as little as $US150 per patient.

17 Mar 2015

Common herpes drug Valacyclovir decreases HIV-1 levels

Case Western Reserve researchers are part of an international team that has discovered that a common herpes drug reduces HIV-1 levels — even when patients do not have herpes.

16 Mar 2015

Mylan releases Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr in U.S.

Mylan N.V. and Mylan Inc. today announced the U.S. launch of its Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr, adding to its existing offering of Fentanyl Transdermal System 12, 25, 50, 75 and 100 mcg/hr.

11 Mar 2015

Simple low-cost intervention could help reduce HIV-related deaths in Africa

A new approach to care for patients with advanced HIV in Tanzania and Zambia, combining community support and screening for a type of meningitis, has reduced deaths by 28%.

11 Mar 2015

Mylan acquires non-U.S. developed markets specialty and branded generics business from Abbott

Mylan N.V. and Mylan Inc. today announced the successful completion of the acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business.

27 Feb 2015

New research reveals that HIV latency is controlled by the virus itself

New research from the Gladstone Institutes for the first time provides strong evidence that HIV latency is controlled not by infected host cells, but by the virus itself. This fundamentally changes how scientists perceive latency, presenting it as an evolutionarily advantageous phenomenon rather than a biological accident.

27 Feb 2015

Study shows how financial incentives can influence some HIV-positive patients in clinical settings

A new study by the HIV Prevention Trials Network shows that some HIV-positive patients were motivated by financial incentives to take their HIV antiretroviral therapy (ART) medication regularly and maintain control of their HIV - enhancing their own health benefits and reducing the chance of passing the virus on to others.

25 Feb 2015

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

The Medicines Patent Pool announced a licence today with MSD, known as Merck in the United States and Canada, for paediatric formulations of raltegravir, a key medicine approved for children living with HIV four weeks of age and older.

24 Feb 2015

Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan Inc. today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India.

23 Feb 2015

Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers from the Hospital Clinic of Barcelona (Spain) have reviewed ten years' worth of scientific studies on mitochondrial toxicity in pregnant women. Exposure to toxic agents such as viruses, certain drugs, pesticides, alcohol and tobacco cause mitochondrial diseases about which very little is known, and which are transmitted from the mother to the foetus.

20 Feb 2015

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

The HIV Prevention Trials Network has launched two new phase 2 studies, HPTN 076 and HPTN 077, which are designed to evaluate new drugs to protect people from getting infected with HIV.

19 Feb 2015

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

A drug used to treat patients with Crohn's disease and multiple sclerosis has helped scientists confirm how "viral reservoirs" form in patients living with HIV and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, a team of researchers reported recently in the journal PLOS Pathogens.

19 Feb 2015

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).

19 Feb 2015

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

Scientists have created a new molecule that shows promise for controlling HIV without daily antiretroviral drugs. The molecule foils a wider range of HIV strains in the laboratory than any known broadly neutralizing HIV antibody and is more powerful than some of the most potent of these antibodies.

19 Feb 2015

UNICEF and UNAIDS go ‘All In’ to end the AIDS epidemic among adolescents

AIDS has become the second leading cause of death among adolescents globally. Just one in four children and adolescents under the age of 15 have access to life-saving antiretroviral treatment. Deaths are declining in all age groups, except among 10–19 year olds.

17 Feb 2015

UC San Diego School of Medicine project receives 2015 Avant-Garde Award for HIV/AIDS Research

A University of California, San Diego School of Medicine project involving the creation of miniature models of the human brain - developed with stem cells - to study neurological disorders caused by HIV and methamphetamine use has been named one of five recipients of the 2015 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse.

11 Feb 2015

Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

With proposals ranging from innovative therapies to the development of unique organoid models of the brain, five scientists have been selected to receive the 2015 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health. The five scientists will each receive $500,000 per year for five years to support their research.

10 Feb 2015

Researchers identify immune biomarkers that could help predict complications in HIV/TB patients

Doctors treating patients battling both HIV and tuberculosis (TB)--many of whom live in Africa--are faced with the decision when to start those patients on antiretroviral therapy (ART) while they are being treated with antibiotics for active TB disease. Some patients fare well on both interventions, with the immune system in check and the TB controlled.

10 Feb 2015

CWRU researcher receives $3.9 million grant for HIV research

A researcher at Case Western Reserve University School of Medicine has been awarded $3.9 million to determine if the combination of the human immunodeficiency virus (HIV) and drug abuse is a double kick in the gut, leading to organ damage throughout the body.

10 Feb 2015

Researchers develop smartphone accessory for rapid diagnosis of infectious diseases at point of care

A team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering, has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers from a finger prick of blood in just 15 minutes.

5 Feb 2015

Antiretroviral News and Research

Medical experts aim to offer lifesaving treatments to eliminate preventable deaths from AKI by 2025

Common herpes drug Valacyclovir decreases HIV-1 levels

Mylan releases Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr in U.S.

Simple low-cost intervention could help reduce HIV-related deaths in Africa

Mylan acquires non-U.S. developed markets specialty and branded generics business from Abbott

New research reveals that HIV latency is controlled by the virus itself

Study shows how financial incentives can influence some HIV-positive patients in clinical settings

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

UNICEF and UNAIDS go ‘All In’ to end the AIDS epidemic among adolescents

UC San Diego School of Medicine project receives 2015 Avant-Garde Award for HIV/AIDS Research

Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

Researchers identify immune biomarkers that could help predict complications in HIV/TB patients

CWRU researcher receives $3.9 million grant for HIV research

Researchers develop smartphone accessory for rapid diagnosis of infectious diseases at point of care

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News